Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib Phase 2 in Postmenopausal Osteoporosis
NCT00112437Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of odanacatib in postmenopausal osteoporosis, sponsored by Merck & Co.. Started Jun 2005; status: completed.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00112437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112437.